HHGA
ALXN

Halbert Hargrove Global Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Halbert Hargrove Global Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,200
Closed -$229K – 99
2015
Q4 		$229K Buy
+1,200
New +$210K 0.1% 88
2015
Q3 		– Sell
-2,518
Closed -$455K – 166
2015
Q2 		$455K Buy
2,518
+300
+14% +$51.8K 0.11% 97
2015
Q1 		$384K Buy
2,218
+673
+44% +$122K 0.12% 120
2014
Q4 		$286K Sell
1,545
-18
-1% -$3.33K 0.14% 94
2014
Q3 		$259K Buy
+1,563
New +$257K 0.07% 112
2014
Q2 		– Sell
-2,930
Closed -$446K – 143
2014
Q1 		$446K Sell
2,930
-361
-11% -$57.4K 0.14% 49
2013
Q4 		$437K Sell
3,291
-353
-10% -$42.4K 0.14% 51
2013
Q3 		$423K Sell
3,644
-252
-6% -$27.6K 0.14% 50
2013
Q2 		$359K Buy
+3,896
New +$375K 0.13% 64

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Halbert Hargrove Global Advisors's ALXN Position: Q1 2016 in Review

Halbert Hargrove Global Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 1,200 shares — an estimated $229K sold.

Halbert Hargrove Global Advisors first reported a position in ALXN in Q2 2013 and held it in 9 quarters. The position peaked at $455K in Q2 2015. 520 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

  • Halbert Hargrove Global Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Halbert Hargrove Global Advisors sold 1,200 Alexion Pharmaceuticals shares in Q1 2016, an estimated $229K.
  • Halbert Hargrove Global Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 9 quarters.
  • Halbert Hargrove Global Advisors's Alexion Pharmaceuticals position peaked at $455K in Q2 2015.
  • 520 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Halbert Hargrove Global Advisors's 13F filing for Q1 2016, filed 12 May 2016.